Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: bulk (17), mass (61), best part (389)

AmB-LISOCEL-Cyclophosphamide (300)-Fludarabine (30)

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY AmB – LISOCEL – CYCLOPHOSPHAMIDE (300) – FLUDARABINE (30) Ambulatory Reg
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/AmB-LISOCEL-Cyclophosphamide-300-Fludarabine-30.pdf

2025 WRES report and action plan

Description: Workforce Race Equality Standard Annual Report 2025 1 Executive Summary WRES Data has been submitted by the Trust since 2
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Equality-reports/2025-wres-report-and-action-plan.pdf

Lisocel – Cyclophosphamide (300) – Fludarabine (30) Ver1

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY LISOCEL – CYCLOPHOSPHAMIDE (300) – FLUDARABINE (30) This regimen will only be avai
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Lisocel-–-Cyclophosphamide-300-–-Fludarabine-30.pdf

Workforce Race Equality Standard annual report 2024

Description: Executive Summary WRES Data has been submitted by the Trust since 2015 and progress is reviewed against the nine indicators contained wit
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Equality-reports/UHS-WRES-report-2024.pdf

AmB-Axicabtagene ciloleucel-Cyclophosphamide (500)-Fludarabine (30)

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY Large B-cell Lymphoma (LBL) AmB- AXICEL – CYCLOPHOSPHAMIDE (500) – FLUDARABINE (30
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/AmB-Axicabtagene-ciloleucel-Cyclophosphamide-500-Fludarabine-30.pdf

Papers-CoG-24.07.2024

Description: Date Time Location Chair Agenda Council of Governors 24/07/2024 14:00 - 16:00 Conference Room, Heartbeat/Microsoft Teams Jenni Douglas-
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Governors/Papers-CoG-24.07.2024.pdf

Finance and Performance Reports 2024-25 Month 2 May 2024

Description: Report to the Trust Board of Directors Title: Agenda item: Sponsor: Author: Date: Purpose: Finance Report 2024-25 Mont
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Trust-governance-and-corporate-docs/2024-Trust-documents/Finance-and-Performance-Reports-2024-25-Month-2-May-2024.pdf

Standing Financial Instructions

Description: These Standing Financial Instructions (SFIs) are issued for the regulation of the conduct of Trust members and officers in relation to
Url: /Media/UHS-website-2019/Docs/About-the-Trust/Finance/StandingFinancialInstructions.pdf

AmB - Brexucel - Cyclophosphamide (500) - Fludarabine (30)

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY Mantle Cell lymphoma (MCL) AmB – BREXUCEL – CYCLOPHOSPHAMIDE (500) – FLUDARABINE (
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/AmB-Brexucel-Cyclophosphamide-500-Fludarabine-30-Ver-1.pdf

Tisacel-Cytarabine (500)-Etoposide (150)

Description: Chemotherapy Protocol CHIMERIC ANTIGEN RECEPTOR T-CELL (CAR-T) THERAPY ALL – TISACEL – CYTARABINE
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/ALL/Tisacel-Cytarabine-500-Etoposide-150.pdf

121 to 130 of 539

Previous … 11 12 13 14 15 … Next